Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021707 | 0.81 | CHRM4 (0.45) | OPRL1CHRM4CHRM2 | |
| SCHEMBL21216421 | 0.80 | OPRL1 (0.39) | OPRL1CHRM4CHRM2TGFBR1 | |
| SCHEMBL24350922 | 0.78 | CHRM4 (0.51) | CHRM4CHRM2 | |
| SCHEMBL365001 | 0.77 | HTR1A (0.39) | OPRL1CHRM4SSTR4CHRM2TGFBR1 | |
| SCHEMBL26265818 | 0.74 | CHRM4 (0.37) | OPRL1CHRM4CHRM2TGFBR1 | |
| SCHEMBL13819907 | 0.73 | RIPK1 (0.44) | OPRL1RIPK1 | |
| SCHEMBL369916 | 0.73 | SSTR4 (0.38) | OPRL1SSTR4 | |
| SCHEMBL26269233 | 0.73 | MEN1 (0.42) | CHRM4CHRM2 | |
| SCHEMBL23841511 | 0.73 | CHRM4 (0.40) | OPRL1CHRM4CHRM2 | |
| SCHEMBL16880332 | 0.72 | CHRM4 (0.47) | CHRM4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | OPRL1 3934/4885CHRM4 4847/4885SSTR4 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.